ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 – FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS

Glioblastoma (GBM) remains the deadliest of all primary brain tumors with very few effective treatment options. Recently, we reported that high AXL expression is correlated with poor prognosis in GBM patients and demonstrated the therapeutic benefits of targeting AXL, a member of TAM receptor tyrosi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Ghosh, Sadashib, Sadahiro, Hirokazu, Kang, Kyung-Don, Gibson, Justin T, Minata, Mutsuko, Yu, Hai, Shi, Junfeng, Chhipa, Rishi, Chen, Zhihong, Lu, Songjian, Simoni, Yannick, Furuta, Takuya, Sabit, Hemragul, Zhang, Suojun, Bastola, Soniya, Yamaguchi, Shinobu, Alsheikh, Heba Allah, Komarova, Svetlana, Wang, Jun, Kim, Sung-Hak, Hambardzumyan, Dolores, Lu, Xinghua, Newell, Evan W, Dasgupta, Biplab, Nakada, Mitsutoshi, Lee, L James, Nabors, L Burt, A. Norian, Lyse, Nakano, Ichiro
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216174/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.054
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados